Krystal Biotech Seizes Moment of Opportunity as VYJUVEK Achieves Record Revenue Growth
The first quarter 2026 conference call for Krystal Biotech, Inc. was a momentous occasion for the company, marking a decade since its inception. Chairman and Chief Executive Officer Krish Krishnan shared his excitement about the next 12 to 24 months being one of the most thrilling periods in Krystal's history.
During this quarter, the company delivered another global revenue growth with net revenue of $116.4 million, making it a remarkable achievement for VYJUVEK. This brings cumulative net VYJUVEK revenue since launch to more than $846 million. Krish expressed his satisfaction with this performance, which represents a 9% sequential growth versus the previous quarter.
The impressive growth is despite a higher-than-usual level of insurance changes during the first quarter. Gross margin was 95%, and the company delivered its 11th consecutive quarter of positive earnings per share (EPS). Outside the United States, VYJUVEK's launch in Europe and Japan is still in its early stages, but progress overseas has been encouraging.
Laurent Goux, Executive Vice President and General Manager for Europe, highlighted that they are also working to add two additional major European markets, Italy and Spain, later this year. Christine Wilson, Senior Vice President and Head of US Commercial, provided more detail on VYJUVEK commercial dynamics and the opportunity ahead.
Another notable achievement was the FDA's granting of platform technology designations to both KB407 for CF and KB111 for Hailey-Hailey disease. These designations have profound implications for Krystal Biotech, allowing them to streamline interactions with the agency and development plans. This advantage is presently unique to the company and one they intend to leverage fully.
Suma Krishnan, President, Research & Development, will provide details on the clinical pipeline, which includes platform technology designations that bring a compounding advantage. These designations allow Krystal to rapidly advance programs into registrational studies, reducing development risk, cost, and time for future programs.
The company's disciplined approach has enabled them to maintain a strong balance sheet while generating meaningful operating leverage. Their commitment to not accessing the capital market since 2022 reflects their dedication to financial strength.
